Ruijin reports 600 patients treated with its domestically produced proton system

Shanghai Ruijin Hospital reported that its SAPT-PS-01 proton therapy system had treated 600 tumour patients by April 15, 2025. The hospital, affiliated with Shanghai Jiao Tong University School of Medicine, discussed the service at a briefing covered by the city government the following day.

Clinical use since the 2023 introduction

The domestically produced system was formally introduced into clinical service at Ruijin in November 2023. The reported total of 600 refers to treatment with this device since that clinical introduction.

By April 2025, the hospital said the system's treatment scope had expanded to nearly fifty tumour types and covered common radiotherapy indications. These figures describe the hospital's clinical activity and the range it reported for this proton system.

Targeting tumours while sparing nearby tissue

The clinical rationale presented by the hospital was precise radiation delivery to the tumour while reducing exposure of surrounding healthy tissue. Doctors emphasized this balance for patients in whom long-term treatment effects are a particular concern.

The groups discussed included children, adults with central nervous system tumours, head and neck tumours, and tumours in anatomically complex locations. The report described these as areas where protection of nearby tissues is especially relevant to treatment planning.

Experience with children

Ruijin reported introducing pediatric proton therapy in Shanghai in August 2023, before the system's formal clinical unveiling that November.

The hospital had treated 23 children with the system by the April briefing. The youngest was three years old. Proton-team doctor Gao Yunsheng said treatment had proceeded smoothly in the children treated so far, with good outcomes and safety.

The hospital also reported follow-up data covering survival, tumour control and treatment toxicity.